Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leila Chebane

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Drug Safety|February 18, 2016
Comment on: "Drug-Induced Hyperglycaemia and Diabetes"Jean-Louis Montastruc, Leila Chebane, Haleh Bagheri
Therapie|July 10, 2016
[Not Available]Leila Chebane, Neda Tavassoli, Haleh Bagheri, et al.
Therapie|December 15, 2010
[Drug-induced hyperglycemia: a study in the French pharmacovigilance database]Leila Chebane, Neda Tavassoli, Haleh Bagheri, et al.
Diagnostics (Basel, Switzerland)|July 2, 2021
Renal Complications Related to Checkpoint Inhibitors: Diagnostic and Therapeutic StrategiesJulie Belliere, Julien Mazieres, Nicolas Meyer, et al.
European Journal of Clinical Pharmacology|November 1, 2016
Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson's diseaseFrançois Montastruc, Florence Moulis, Mélanie Araujo, et al.
Journal of General Internal Medicine|December 20, 2018
What Fluoroquinolones Have the Highest Risk of Aortic Aneurysm? A Case/Non-case Study in VigiBase®Agnès Sommet, Justine Bénévent, Vanessa Rousseau, et al.
Human Psychopharmacology|May 1, 2020
Drug-induced tics: An observational postmarketing studyDavy Touafchia, François Montastruc, Maryse Lapeyre-Mestre, et al.
Drug Safety|March 9, 2020
Fluoroquinolone-Induced Photosensitivity: A Chemical Fragment-Based Approach by a Case/Non-case Study in VigiBase<sup>®</sup>Yoann Zelmat, Vanessa Rousseau, Leila Chebane, et al.
British Journal of Clinical Pharmacology|May 30, 2020
Can tramadol really induce hyponatraemia? A pharmacovigilance studyClaire de Canecaude, Vanessa Rousseau, Leila Chebane, et al.
Therapie|March 19, 2025
Intravitreal vascular endothelial growth factor inhibitors and cardiovascular adverse drug reactions: Added value of the data of the French pharmacovigilance spontaneous reporting assessmentAurélie Bobet, Leila Chebane, Annie-Pierre Jonville-Bera, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Drug Safety|February 18, 2016
Comment on: "Drug-Induced Hyperglycaemia and Diabetes"Jean-Louis Montastruc, Leila Chebane, Haleh Bagheri
Therapie|July 10, 2016
[Not Available]Leila Chebane, Neda Tavassoli, Haleh Bagheri, et al.
Therapie|December 15, 2010
[Drug-induced hyperglycemia: a study in the French pharmacovigilance database]Leila Chebane, Neda Tavassoli, Haleh Bagheri, et al.
Diagnostics (Basel, Switzerland)|July 2, 2021
Renal Complications Related to Checkpoint Inhibitors: Diagnostic and Therapeutic StrategiesJulie Belliere, Julien Mazieres, Nicolas Meyer, et al.
European Journal of Clinical Pharmacology|November 1, 2016
Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson's diseaseFrançois Montastruc, Florence Moulis, Mélanie Araujo, et al.
Journal of General Internal Medicine|December 20, 2018
What Fluoroquinolones Have the Highest Risk of Aortic Aneurysm? A Case/Non-case Study in VigiBase®Agnès Sommet, Justine Bénévent, Vanessa Rousseau, et al.
Human Psychopharmacology|May 1, 2020
Drug-induced tics: An observational postmarketing studyDavy Touafchia, François Montastruc, Maryse Lapeyre-Mestre, et al.
Drug Safety|March 9, 2020
Fluoroquinolone-Induced Photosensitivity: A Chemical Fragment-Based Approach by a Case/Non-case Study in VigiBase<sup>®</sup>Yoann Zelmat, Vanessa Rousseau, Leila Chebane, et al.
British Journal of Clinical Pharmacology|May 30, 2020
Can tramadol really induce hyponatraemia? A pharmacovigilance studyClaire de Canecaude, Vanessa Rousseau, Leila Chebane, et al.
Therapie|March 19, 2025
Intravitreal vascular endothelial growth factor inhibitors and cardiovascular adverse drug reactions: Added value of the data of the French pharmacovigilance spontaneous reporting assessmentAurélie Bobet, Leila Chebane, Annie-Pierre Jonville-Bera, et al.
Pageof 4